EU/3/12/1001

About

Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in April 2015 on request of the Sponsor.

On 6 June 2012, orphan designation (EU/3/12/1001) was granted by the European Commission to Abbott Laboratories, United Kingdom, for 1-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl] thieno [3,2-c]pyridin-3-yl}phenyl)-3-(3-fluorophenyl)urea for the treatment of ovarian cancer.

The sponsorship was transferred to AbbVie Ltd, United Kingdom, in January 2013.

For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.

Key facts

Active substance
1-(4-{4-Amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl] thieno [3,2-c]pyridin-3-yl}phenyl)-3-(3-fluorophenyl)urea
Disease / condition
Treatment of ovarian cancer
Date of decision
06/06/2012
Outcome
Withdrawn
Orphan decision number
EU/3/12/1001

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

AbbVie Ltd
Abbott House
Vanwall Business Park
Vanwall Road
Maidenhead
Berkshire
SL6 4XE
United Kingdom
Tel. +44 (0)1628 644501
Fax +44 (0)1628 672624
E-mail: orphandrugs.enquiries@abbvie.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating